FDA clears – After a dispute with the U.S. Food and Drug Administration, UniQure says the agency has reversed course on its experimental Huntington’s treatment, AMT-130, clearing the company to submit for accelerated approval in the third quarter.
When the FDA moved to block UniQure’s path to marketing approval for its experimental Huntington’s treatment, it wasn’t just a bureaucratic delay. For a closely watched drug built around the hope of changing lives, it threatened to put the next step out of reach.
On Wednesday, the biotech company said the Food and Drug Administration has now reversed its opposition, clearing the way for UniQure to file for U.S. approval of AMT-130.
UniQure plans to submit a marketing application in the third quarter, seeking accelerated approval for AMT-130. The company linked the shift to a recent meeting with FDA officials. during which the agency agreed that a three-year analysis of an early-stage study showing a benefit for patients with Huntington’s would be “acceptable” to support a marketing application.
The change lands on data that have been at the center of a public tug-of-war over what’s enough to move forward. UniQure said the same AMT-130 results were previously judged insufficient by former FDA officials. including Commissioner Marty Makary and Vinay Prasad. who had served as the agency’s top regulator of cell and gene therapies.
That sequence—opposition, then agreement—reshapes the stakes for everyone watching Huntington’s drug development. A timeline that once appeared to stall now points toward an application submission, built around the same study analysis that has already split regulators and critics.
For UniQure, the decision means a door has opened at the FDA. For patients and families who live with Huntington’s. it means the next chapter may arrive sooner than expected—but only after a filing and whatever comes next in the review process. And for the broader field of cell and gene therapies. the message is just as sharp: what the FDA considers “acceptable” can change with the conversation that happens in the room—long after the data are already on the table.
UniQure AMT-130 Huntington’s disease FDA accelerated approval cell and gene therapies marketing application
So they cleared it like… today? I don’t trust FDA “reversed course” stuff.
My cousin has Huntington’s and I swear every time I hear “accelerated approval” it ends up taking forever anyway. Also three-year analysis?? That sounds like they’re just buying time.
Wait so is AMT-130 already approved in the US or are they still asking permission? The article says cleared to seek approval but then “acceptable” study analysis like what does that even mean. Sounds like paperwork winning again.
This is kinda wild because I saw something earlier saying FDA was blocking it because of “not enough benefit,” and now it’s acceptable after a meeting. I’m not saying it’s bad, I’m just like… who decides when the goalposts move? Also Huntington’s families deserve better than delays and meetings.